Bespak, a specialist inhalation contract development and manufacturing organisation (CDMO) focused exclusively on inhaled and nasal drug delivery, will continue expansion of its next-generation nasal drug delivery offering with the launch of NasaDose ultra soft unit dose spray, a device that combines Bespak’s established NasaDose unit dose platform with proprietary soft mist technology from its joint venture, Resyca.
The launch of NasaDose Ultra Soft Unit Dose Spray further strengthens Bespak’s expanded nasal drug delivery offering. It follows Bespak’s recently announced collaboration with Upperton, a specialist formulation development CDMO, which brings together expertise in formulation, device engineering, clinical supply and commercial manufacture. Together with specialist technologies from partners including Resyca, the offering supports liquid, soft mist and dry powder nasal products from early development through to commercial supply.
NasaDose ultra soft unit dose spray combines, for the first time, differentiated drug delivery technologies from Bespak and Resyca to create a unique intranasal delivery solution for gentle yet precise nasal delivery.
Resyca’s soft mist technology generates a fine, low-velocity nasal spray providing consistent aerosol performance with low mechanical shear, supporting the delivery of sensitive and complex formulations.
Bespak’s spring-powered actuation mechanism is engineered to deliver a repeatable dose largely independent of user actuation speed, reducing operator variability and supporting consistent performance.
The device allows key performance parameters, including spray characteristics, dose volume and actuation force, to be configured according to formulation requirements and target patient populations, and enables precise and controlled deposition within the nasal cavity, including targeted delivery to the turbinate and olfactory regions.
NasaDose ultra soft unit dose spray ay is designed to support the delivery of both conventional small molecules and formulations including proteins, peptides and other complex biologics that may be susceptible to degradation during aerosolisation, making it suitable for applications including local nasal therapies, prophylaxis, vaccines and systemic delivery, with particular potential for nose-to-brain and CNS therapies.
